Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTH recombinant plasmid
- Development stage
- Phase 2
- Lead developer
- Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
PTH recombinant plasmid is a gene therapy drug designed to treat hypoparathyroidism by delivering the gene for parathyroid hormone (PTH). Once delivered, the plasmid enables cells to produce biologically active PTH, which is crucial for regulating calcium and phosphate homeostasis. This approach aims to restore normal PTH levels in patients who are deficient in the hormone.
- Other names
- recombinant parathyroid hormone plasmidrecombinant human parathyroid hormone (1-84) plasmid injectionhPTH plasmidhPTH(1-84) plasmid
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on PTH recombinant plasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTH recombinant plasmid.